DRD2 and gastric cancer: In addition, one recent study showed that the expression of dopamine receptor D2 (DRD2) was negatively correlated with survival durations in patients with gastric cancer, and thus DRD2 antagonists were considered a possible efficient choice in gastric cancer therapy.9 The mixed findings provide the impetus for further exploration of this possible link.